The prospects for cisplatin and nab-paclitaxel combination therapy in patients with pre-treated triple-negative breast cancer. Description of the clinical case.
| Autor: | L. G. Zhukova, K. S. Bardovskaya, E. V. Lubennikova, I. R. Suslova |
|---|---|
| Jazyk: | ruština |
| Rok vydání: | 2018 |
| Předmět: | |
| Zdroj: | Медицинский совет, Vol 0, Iss 10, Pp 49-55 (2018) |
| Druh dokumentu: | article |
| ISSN: | 2079-701X 2658-5790 |
| DOI: | 10.21518/2079-701X-2018-10-49-55 |
| Popis: | Molecular and biological features of triple negative breast cancer (TN BC) determine the limited possibilities of systemic therapy and, as a consequence, the more aggressive course of the disease. Taxanes are one of the most effective chemotherapies used in breast cancer therapy. The special form of paclitaxel nab-paclitaxel makes it possible to obtain an objective and a subjective effect, which is especially important in the pre-treated patients. In addition, the drug has a favourable safety profile and a well-controlled toxicity.The article contains a review of the literature on the prospects for the use of nab-paclitaxel in breast cancer, especially in its triple negative version, and a description of the clinical case of therapy with a combination of cisplatin and nab-paclitaxel in a young patient with BRCA-1-associated TN breast cancer. |
| Databáze: | Directory of Open Access Journals |
| Externí odkaz: |
|